Document:

Exhibit 4.3

 

WARRANT AGREEMENT

 

NeuroMetrix, Inc.

 

and

 

American Stock Transfer & Trust Company,
LLC, as Warrant Agent

 

WARRANT AGREEMENT

 

THIS WARRANT AGREEMENT (this “Agreement”),
dated as of [•], 2015, is by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and
American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as Warrant Agent (the “Warrant
Agent”). 

 

WHEREAS, the Company is engaged in a public
offering (the “Offering”) of common stock of the Company, par value $0.0001 per share (“Common Stock”)
and [up to] [•] warrants to public investors in the Offering, each such warrant evidencing the right of the
holder, thereof to purchase one share of Common Stock of the Company for $[•] per share, subject to adjustment as described
herein (the “Warrants”);

 

WHEREAS, the Company has filed with the
Securities and Exchange Commission (the “Commission”) a registration statement, as amended, on Form S-1, No.
333-188133 (the “Registration Statement”) and prospectus (the “Prospectus”), for the registration,
under the Securities Act of 1933, as amended (the “Securities Act”), of the shares of Common Stock and the Warrants
to be sold in the Offering and the shares of Common Stock underlying the Warrants (the “Warrant Shares”);

 

WHEREAS, the Company desires the Warrant
Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration,
transfer, exchange and exercise of the Warrants;

 

WHEREAS, the Company desires to provide
for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights,
limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants (each a “Holder”);
and 

 

WHEREAS, all acts and things have been
done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on
behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the
execution and delivery of this Agreement.

 

NOW, THEREFORE, in consideration of the mutual agreements herein
contained, the parties hereto agree as follows:

 

		1.	Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the
Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and
conditions set forth in this Agreement.

 

    	1

    	 

    

  

		2.	Warrants.

 

		2.1.	Form of Warrant. Each Warrant shall be issued in registered form only and shall be in substantially the form of Exhibit
A hereto, the provisions of which are incorporated herein. Each Warrant shall be signed by, or bear the facsimile signature
of, the President, Chief Executive Officer, Chief Financial Officer, Secretary or other authorized officer of the Company. In the
event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which
such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased
to be such at the date of issuance.

 

		2.2.	Effect of Countersignature. Unless and until countersigned by, or issued bearing the facsimile signature of, the Warrant
Agent pursuant to this Agreement, a Warrant shall be invalid and of no effect and may not be exercised by the holder thereof.

 

		2.3.	Registration.

 

		2.3.1.	Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”) for the registration
of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent
shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance
with instructions delivered to the Warrant Agent by the Company.

 

		2.3.2.	Registered Holder. Prior to due presentment to the Warrant Agent for registration of transfer of any Warrant, the Company
and the Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered
Holder”) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation
of ownership or other writing on the Warrant Certificate (as defined below) made by anyone other than the Company or the Warrant
Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall
be affected by any notice to the contrary.

 

		3.	Terms and Exercise of Warrants.

 

		3.1.	Exercise Price. Each Warrant shall, when countersigned by the Warrant Agent, entitle the Registered Holder thereof,
subject to the provisions of such Warrant and of this Warrant Agreement, to purchase from the Company the number of shares of Common
Stock stated therein, at the price of $[•] per share, subject to the adjustments provided herein. The term “Exercise
Price” as used in this Warrant Agreement shall mean the price per share at which shares of Common Stock may be purchased
at the time a Warrant is exercised.

 

		3.2.	Duration of Warrants. A Warrant may be exercised only during the period (the “Exercise Period”) commencing
on the date of issuance thereof and ending on April [•], 2020 (the “Expiration Date”); provided,
however, that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth
in subsection 3.3.2 below with respect to an effective registration statement. Each Warrant not exercised on or before the Expiration
Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at 5:00 p.m.
New York City time on the Expiration Date.

 

    	2

    	 

    

  

		3.3.	Exercise of Warrants.

 

		3.3.1.	Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant countersigned by the Warrant Agent may
be exercised by the Registered Holder thereof by surrendering it, at the office of the Warrant Agent, or at the office of its successor
as Warrant Agent, in the City of New York in the State of New York, with the subscription form, as set forth in the Warrant, duly
executed, and by paying in full the Exercise Price*** for each full share of Common Stock as to which the Warrant is exercised
and any and all applicable taxes due in connection with the exercise of the Warrant. The aggregate Exercise Price shall be paid
(a) in lawful money of the United States, by wire transfer, in good certified check or good bank draft payable to the order of
the Warrant Agent or (b) by Cashless Exercise (as defined below) in accordance with Section 3.2.2 hereof. Upon delivery
of an exercise notice, the Holders shall be deemed for all corporate purposes to have become the holder of record of the Warrant
Shares with respect to which a Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s
DTC account or the date of delivery of the certificates evidencing such Warrant Shares (as the case may be).

 

***Checks should be payable to American Stock Transfer.
Originals need to be mailed to American Stock Transfer, Attention: [Adrian Diaz]. Wired funds for exercise should be wired to:

 

[•]

ABA # [•]

ACCT # [•]

ACCT NAME: AMERICAN STOCK TRANSFER & TRUST CO

AS AGENT FOR WARRANTS

ATTN: [•]

 

		3.3.2.	Cashless Exercise. Notwithstanding anything contained herein to the contrary, if and only if an effective registration
statement covering the issuance of the Warrant Shares is not available, the Registered Holder may exercise this
Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such
exercise in payment of the aggregate Exercise Price, and elect instead to receive upon such exercise the “Net Number”
of shares of Common Stock determined according to formula below (a “Cashless Exercise”). In that case,
the Registered Holder shall deliver to the Company a duly executed facsimile copy of the Notice of Exercise form annexed hereto
(the “Exercise Notice”). In no event shall the Company be required to (i) net cash settle the Warrant
exercise or (ii) issue, upon a Cashless Exercise pursuant to this Section 3.3.2, more shares of Common Stock than it then
has authorized under its certificate of incorporation, as amended and/or restated from time to time. In case of a Cashless Exercise,
the following formula applies:

	 	 	 
	Net Number =	 	
        (A ×
        B) – (A × C)

	 	 	B

 

    	3

    	 

    

  

For purposes of the foregoing formula:

 

	A	 	=	 	the total number of shares with respect to which this Warrant is then being exercised.
	 	 	 
	B	 	=	 	the arithmetic average of the Closing Sale Prices (as defined below) of the Common Stock for the five (5) consecutive Trading Days ending on the date immediately preceding the date of the Exercise Notice.
	 	 	 
	C	 	=	 	the Exercise Price then in effect for the applicable shares of Common Stock at the time of such exercise.

 

The term “Closing Sale Price”
means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security
on the NASDAQ Capital Market, as reported by Bloomberg, or, if the Nasdaq Capital Market begins to operate on an extended hours
basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or the
last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the NASDAQ
Capital Market is not the principal securities exchange or trading market for such security, the last closing bid price or last
trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed
or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively,
of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or,
if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices,
or the ask prices, respectively, of any market makers for such security as reported in the OTC Link or “pink sheets”
by OTC Markets Group Inc. (formerly Pink OTC Markets Inc.). If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value
as mutually determined by the Company and the Registered Holder. If the Company and the Registered Holder are unable to agree upon
the fair market value of such security, then such dispute shall be resolved pursuant to Section 8.3 hereof. All such determinations
to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable
calculation period. 

 

For purposes of Rule 144(d) promulgated
under the Securities Act, as in effect on the date hereof, assuming the Registered Holder is not an affiliate of the Company, the
shares of Common Stock issued in a Cashless Exercise shall be deemed to have been acquired by the Registered Holder, and the holding
period for the shares of Common Stock shall be deemed to have commenced, on the date this Warrant was originally issued.

 

    	4

    	 

    

  

		3.3.3.	Issuance of Common Stock on Exercise. As soon as
                                         practicable after the exercise of any Warrant and the clearance of the funds in payment
                                         of the Exercise Price (if payment is pursuant to subsection 3.3.1(a)), the Company
                                         shall issue to the Registered Holder of such Warrant a certificate or certificates or,
                                         if in uncertificated form, evidence of electronic ownership in book-entry form, for the
                                         number of full shares of Common Stock to which he, she or it is entitled, registered
                                         in such name or names as may be directed by him, her or it, and if such Warrant shall
                                         not have been exercised in full, a new countersigned Warrant for the number of shares
                                         as to which such Warrant shall not have been exercised. Notwithstanding the foregoing,
                                         the Company shall not be obligated to deliver any shares of Common Stock pursuant to
                                         the cash exercise of a Warrant and shall have no obligation to settle such Warrant exercise
                                         unless (1) a registration statement under the Securities Act with respect to the Warrant
                                         Shares is then effective and a prospectus relating thereto is current or (2) the Common
                                         Stock issuable upon such Warrant exercise has been registered, qualified or deemed to
                                         be exempt under the federal securities laws and the securities laws of the state of residence
                                         of the Registered Holder of the Warrants. Subject to Section 4.5 of this Agreement,
                                         a Registered Holder of Warrants may exercise its Warrants only for a whole number of
                                         shares of Common Stock. In no event will the Company be required to net cash settle the
                                         Warrant. If, by reason of any exercise of warrants, the holder of any Warrant would be
                                         entitled, upon the exercise of such Warrant, to receive a fractional interest in a share,
                                         the Company shall either (i) round up to the nearest whole number, the number of shares
                                         to be issued to such holder or (ii) pay such holder cash for such fractional share in
                                         the Company’s sole discretion. In the event of a cash exercise, the Company hereby
                                         instructs the Transfer Agent to record cost basis for newly issued shares as the Exercise
                                         Price paid for the share(s).

 

		3.3.4.	Valid Issuance. All Common Stock issued or issuable upon the proper exercise of a Warrant in conformity with this Agreement
shall be validly issued, fully paid and nonassessable.

 

    	5

    	 

    

  

		3.4.	Beneficial Ownership Limitation on Exercises. The Company shall not affect the exercise of any portion of a Warrant,
and the Registered Holder of such Warrant shall not have the right to exercise any portion of such Warrant, to the extent that
after giving effect to such exercise, the Registered Holder (together with the Registered Holder’s affiliates, and any persons
acting as a group together with the Holder or any Registered Holder’s affiliates) would beneficially own in excess of 4.99%
(the “Maximum Percentage”) of the Common Stock outstanding immediately after giving effect to such exercise,
provided, however, that the foregoing limitation on exercise shall not apply to any Registered Holder who, together
with such Registered Holder’s affiliates, and any persons acting as a group together with such Registered Holder and such
Registered Holder’s affiliates, owns in excess of the Maximum Percentage immediately prior to the closing of the Offering.
For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Registered Holder
and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which
the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise
of the remaining, unexercised portion of the Warrant beneficially owned by the Registered Holder and its affiliates and (ii) exercise
or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Registered
Holder and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Registered Holder
or any of its affiliates. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall
be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
To the extent that the limitation contained in this Section 3.4 applies, the Registered Holder’s submission of an
Election to Purchase shall be deemed to be the Registered Holder’s determination of whether a Warrant is exercisable (in
relation to any other securities owned by the Registered Holder together with any affiliates) and of which portion of a Warrant
is exercisable, in each case subject to the Maximum Percentage, and the Company shall have no obligation to verify or confirm the
accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of the Warrants,
in determining the number of outstanding shares of Common Stock, the Registered Holder may rely on the number of outstanding shares
of Common Stock as reflected in the most recent of (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on
Form 8-K or other public filing with the Commission, as the case may be, (2) a more recent public announcement by the Company or
(3) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. For any
reason at any time, upon the written or oral request of the Registered Holder, the Company shall within three (3) trading days
confirm to the Registered Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
any Warrant, by the Registered Holder and its affiliates since the date as of which such number of outstanding shares of Common
Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum
Percentage applicable to such holder to any other percentage specified in such notice; provided, however, that any
such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.

 

		4.	Adjustments.

 

		4.1.	Stock Dividends.

 

		4.1.1.	Split-Ups. If after the date hereof, and subject to the provisions of Section 4.5 below, the number of outstanding
shares of Common Stock is increased by a stock dividend payable in Common Stock, or by a split-up of Common Stock or other similar
event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable
on exercise of each Warrant shall be increased in proportion to such increase in the outstanding shares of Common Stock and the
Exercise Price shall be proportionally decreased such that the aggregate Exercise Price, after such adjustments, remains the same
for each Warrant.

 

    	6

    	 

    

  

		4.1.2.	Dividends and Other Distributions. If the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction), except to the extent an adjustment was already made pursuant
to Section 4.1.1 or 4.2 (a “Distribution”), at any time after the issuance of this Warrant, then,
in each such case, the Company shall reserve and put aside the maximum Distribution amount the Holder would have been entitled
to receive if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date
on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common
Stock are to be determined for the participation in such Distribution. Upon exercise of this Warrant, in whole or in part, the
Company shall, contemporaneously with the delivery of the Warrant Shares, distribute to the Holder a pro rata portion of such Distribution
based on the portion of the Warrant that has been exercised (provided, however, to the extent that the Holder’s
right to participate in any such Distributions would result in the Holder exceeding the Maximum Percentage, then the Holder shall
not be entitled to participate in such Distribution at such time and to such extent (or the beneficial ownership of any such Common
Stock as a result of such Distribution to such extent) and such Distribution to such extent shall be held in abeyance for the benefit
of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage, at
which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution
or on any subsequent Distribution to be held similarly in abeyance) to the same extent as if there had been no such limitation).

 

		4.2.	Aggregation of Shares. If after the date hereof, and subject to the provisions of Section 4.5 hereof, the number
of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of
Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification
or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in proportion to
such decrease in outstanding shares of Common Stock and the Exercise Price shall be proportionally increased such that the aggregate
Exercise Price, after such adjustments, remains the same for each Warrant.

 

		4.3.	Calculations. All calculations under this Section 4 shall be made to the nearest cent or the nearest whole share,
as the case may be. For purposes of this Section 4, any calculation of the number of shares of Common Stock deemed to be
issued and outstanding as of a given date shall not include treasury shares, if any. Notwithstanding anything to the contrary in
this Section 4, no adjustment in the Exercise Price shall be required unless such adjustment would require an increase or
decrease of at least 1% in such price; provided, however, that any adjustments which by reason of the immediately
preceding sentence are not required to be made shall be carried forward and taken into account in any subsequent adjustment. In
any case in which this Section 4 shall require that an adjustment in the Exercise Price be made effective as of a record
date for a specified event, if the Registered Holder exercises a Warrant after such record date, the Company may elect to defer,
until the occurrence of such event, the issuance of the shares of Common Stock and other capital stock of the Company in excess
of the shares of Common Stock and other capital stock of the Company, if any, issuable upon such exercise on the basis of the Exercise
Price in effect prior to such adjustment; provided, however, that in such case the Company or the Warrant Agent shall deliver to
the Registered Holder a due bill or other appropriate instrument evidencing the Registered Holder’s right to receive such
additional shares and/or other capital securities upon the occurrence of the event requiring such adjustment.

 

    	7

    	 

    

 

		4.4.	Notices of Changes in Warrant. Upon every adjustment of the Exercise Price or the number of shares issuable upon exercise
of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting
from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise
of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.
Upon occurrence of any event specified in Sections 4.1 or 4.2, the Company shall give written notice of the occurrence
of such event to each Warrant holder, at the last address set forth for such holder in the Warrant Register, of the record date
or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity
of such event.

 

		4.5.	No Fractional Shares. Notwithstanding any provision contained in this Warrant Agreement to the contrary, the Company
shall not issue fractional shares upon exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4,
the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the
Company shall, upon such exercise, round to the nearest whole number, the number of the shares of Common Stock to be issued to
such holder.

 

		4.6.	Form of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section 4,
and Warrants issued after such adjustment may state the same Exercise Price and the same number of shares as is stated in the Warrants
initially issued pursuant to this Agreement; provided, however, that the Company may at any time in its sole discretion
make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and
any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may
be in the form as so changed.

 

		4.7.	Other Events. In case any event shall occur affecting the Company as to which none of the provisions of preceding subsections
of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to
(i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each
such case, the Company shall appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized
national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is
necessary to effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment is necessary,
the terms of such adjustment. The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment
recommended in such opinion.

 

		5.	Transfer and Exchange of Warrants.

 

		5.1.	Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant
upon the Warrant Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed by
an eligible guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association,
and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate
number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall
be delivered by the Warrant Agent to the Company from time to time upon request.

 

    	8

    	 

    

  

		5.2.	Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request
for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested
by the Registered Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants.

 

		5.3.	Fractional Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which
shall result in the issuance of a warrant certificate for a fraction of a warrant.

 

		5.4.	Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance
with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5.

 

		6.	Other Provisions Relating to Rights of Holders of Warrants.

 

		6.1.	No Rights as Stockholder. Except as otherwise set forth herein, a Warrant does not entitle the Registered Holder thereof
to any of the rights of a stockholder of the Company, including, without limitation, the right to receive dividends, or other distributions,
exercise any preemptive rights to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders
or the election of directors of the Company or any other matter.

 

		6.2.	Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company
and the Warrant Agent may on such terms as to indemnity bond or otherwise as they may in their discretion impose (which shall,
in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as
the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation
of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by
anyone.

 

		6.3.	Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but
unissued shares of Common Stock that shall be sufficient to permit the full cash exercise (pursuant to Section 3.3.1 of this Agreement)
of all outstanding Warrants issued pursuant to this Agreement.

 

		6.4.	Registration of Common Stock. The Company registered the Warrants and the Warrant Shares in the Registration Statement.
The Company will use its reasonable best efforts to maintain the effectiveness of such Registration Statement and the current status
of the Prospectus or to file and maintain the effectiveness of another registration statement and another current prospectus covering
the Warrants and the Warrant Shares at any time that the Warrants are exercisable. In addition, the Company agrees to use its reasonable
best efforts to register the Warrants and Warrant Shares under the blue sky laws of the states of residence of the Registered Holders
to the extent an exemption from such registration is not available. In no event shall the Company be required to net cash settle
the Warrant exercise or pay any liquidated damages or any penalty for failure to deliver shares of Common Stock pursuant to this
Agreement.

 

    	9

    	 

    

  

		7.	Concerning the Warrant Agent and Other Matters.

 

		7.1.	Payment of Taxes. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the
Company or the Warrant Agent in respect of the issuance or delivery of the Warrant Shares, but neither the Company nor the Warrant
Agent shall be obligated to pay any transfer taxes in respect of the Warrants or Warrant Shares. The Warrant Agent shall not register
any transfer or issue or deliver any Warrants or Warrant Shares unless or until the persons requesting the registration or issuance
shall have paid to the Warrant Agent for the account of the Company the amount of such tax, if any, or shall have established to
the reasonable satisfaction of the Company and the Warrant Agent that such tax, if any, has been paid.

 

		7.2.	Resignation, Consolidation, or Merger of Warrant Agent.

 

		7.2.1.	Appointment of Successor Warrant Agent. The Warrant Agent, or any successor hereafter appointed, may resign its duties
and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the
Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall
appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment
within a period of thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent
or by the holder of a Warrant (who shall, with such notice, submit his Warrant for inspection by the Company), then the holder
of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor
Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall
be a corporation in good standing in the State of New York and having its principal office in the Borough of Manhattan, City and
State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination
by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights,
immunities, duties and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder,
without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall
execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority,
powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall
make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming
to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

 

		7.2.2.	Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give
notice thereof to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of
any such appointment.

 

    	10

    	 

    

  

		7.2.3.	Merger or Consolidation of Warrant Agent. Any company into which the Warrant Agent may be merged or with which it may
be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall
be the successor Warrant Agent under this Agreement without any further act.

 

		7.3.	Fees and Expenses of Warrant Agent.

 

		7.3.1.	Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent
hereunder and any transfer agent fees which are in addition thereto and shall, pursuant to its obligations under this Agreement,
reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its
duties hereunder.

 

		7.3.2.	Further Assurances. The Company agrees to perform, execute, acknowledge and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant
Agent for the carrying out or performing of the provisions of this Agreement.

 

		7.4.	Liability of Warrant Agent.

 

		7.4.1.	Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall
deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any
action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed
to be conclusively proved and established by a statement signed by the President, Chief Executive Officer, Chief Financial Officer
or other authorized officer of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for
any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

 

		7.4.2.	Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad
faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments,
costs and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except
as a result of the Warrant Agent’s gross negligence, willful misconduct or bad faith.

 

		7.4.3.	Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect
to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for
any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not
be responsible for making any adjustments required under the provisions of Section 4 hereof or responsible for the manner,
method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor
shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares
of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of Common Stock shall, when
issued, be valid and fully paid and nonassessable.

 

    	11

    	 

    

  

		7.5.	Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform
the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect
to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase
of Warrant Shares.

 

		8.	Miscellaneous Provisions.

 

		8.1.	Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent
shall bind and inure to the benefit of their respective successors and assigns.

 

		8.2.	Notices. Any notice, statement or demand authorized by this Warrant Agreement to be given or made by the Warrant Agent
or by the holder of any Warrant to or on the Company shall be sufficiently given (i) when so delivered if by hand or overnight
delivery, (ii) when sent, if delivered by facsimile (provided confirmation of transmission is mechanically or electronically generated
and kept on file by the sending party) or by electronic mail, or (iii) if sent by certified mail or private courier service within
five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company
with the Warrant Agent), as follows:

 

NeuroMetrix, Inc.

1000 Winter Street

Waltham, Massachusetts

Attn: Shai Gozani

By Email (which constitutes notice): shai_gozani@neurometrix.com

 

with copies to:

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

Attention: Megan N. Gates

By Email: mngates@mintz.com

 

Any notice, statement or demand authorized by this
Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently given
(i) upon receipt if by hand or overnight delivery, (ii) when sent, if delivered by facsimile (provided confirmation of transmission
is mechanically or electronically generated and kept on file by the sending party) or by electronic mail, or (iii) if sent by certified
mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address
is filed in writing by the Warrant Agent with the Company), as follows:

 

American Stock Transfer & Trust Company, LLC

6201 15th Avenue, 3rd Floor

Brooklyn, NY 11219

Attention: Corporate Actions

 

    	12

    	 

    

  

No fax number available.

By Email (which constitutes
notice): [•]

 

		8.3.	Applicable Law. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed
in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in
the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim
against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of
New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts
represent an inconvenient forum.

 

		8.4.	Persons Having Rights under this Agreement. Nothing in this Agreement shall be construed to confer upon, or give to,
any person or corporation other than the parties hereto and the Registered Holders of the Warrants any right, remedy or claim under
or by reason of this Warrant Agreement or of any covenant, condition, stipulation, promise or agreement hereof. All covenants,
conditions, stipulations, promises and agreements contained in this Warrant Agreement shall be for the sole and exclusive benefit
of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants.

 

		8.5.	Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office
of the Warrant Agent in the Borough of Manhattan, City of New York and State of New York, for inspection by the Registered Holder
of any Warrant. The Warrant Agent may require any such holder to submit his Warrant for inspection by it.

 

		8.6.	Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts
shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.
A signature to this Agreement transmitted electronically shall have the same authority, effect, and enforceability as an original
signature.

 

		8.7.	Effect of Headings. The section headings herein are for convenience only and are not part of this Warrant Agreement
and shall not affect the interpretation thereof.

 

		8.8. 	Amendments. This Agreement may be amended by the parties hereto without the consent of any Registered Holder for the
purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing
any other provisions with respect to matters arising under this Agreement as the parties may deem necessary or desirable and that
the parties deem shall not adversely affect the interest of the Registered Holders. All other modifications or amendments shall
require the written consent of the Company and the Registered Holders holding Warrants to purchase at least 65% of the shares of
Common Stock underlying the then outstanding Warrants. No consideration shall be offered by the Company to any Registered Holder
in connection with a modification, amendment or waiver of this Warrant Agreement or any Warrant without also offering the same
consideration to all Registered Holders.

 

    	13

    	 

    

  

		8.9. 	Severability. This Warrant Agreement shall be deemed severable, and the invalidity or unenforceability of any term or
provision hereof shall not affect the validity or enforceability of this Warrant Agreement or of any other term or provision hereof.
Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added
as a part of this Warrant Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible
and be valid and enforceable.

 

		8.10. 	Survival. The provisions of Section 8 shall survive any termination of this Agreement and the resignation, removal or
replacement of the Warrant Agent.

 

[Signature Page Follows]

 

    	14

    	 

    

  

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be duly executed as of the date first above written.

 

	 	NeuroMetrix, Inc.
	 	 
	 	By:	 
	 	 	Name:	Thomas Higgins
	 	 	Title:	Chief Financial Officer
	 	 	 
	 	American Stock Transfer & Trust Company, LLC, as Warrant Agent
	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

[Signature Page to Warrant Agreement]

 

    	 

    	 

    

  

EXHIBIT A 

 

[FORM OF WARRANT CERTIFICATE] 

 

Number

 

Warrants 

 

THIS WARRANT SHALL BE VOID IF NOT EXERCISED
PRIOR TO 

 

THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED
FOR

 

IN THE WARRANT AGREEMENT DESCRIBED BELOW

 

NEUROMETRIX, INC. 

 

Incorporated Under the Laws of the State
of Delaware 

 

CUSIP [•] 

 

Warrant Certificate 

 

This Warrant Certificate certifies that
_________________, or its registered assigns, is the registered holder of warrant(s) (the “Warrants”
and each, a “Warrant”) to purchase shares of Common Stock, par value $0.0001 per share (“Common Stock”),
of NeuroMetrix, Inc., a Delaware corporation (the “Company”). Each Warrant entitles the holder, upon exercise
during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and
nonassessable shares of Common Stock as set forth below, at the exercise price (the “Exercise Price”) as determined
pursuant to the Warrant Agreement, payable in lawful money (or through “cashless exercise” as provided for in the Warrant
Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the Exercise Price at the
office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement.
Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement
(as defined on the reverse hereof).

 

Each Warrant is initially exercisable
for [___] fully paid and non-assessable share of Common Stock. The number of the shares of Common Stock issuable upon exercise
of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

 

The initial Exercise Price per share of
Common Stock for any Warrant is equal to $ [•] per share. The Exercise Price is subject to adjustment upon the occurrence
of certain events set forth in the Warrant Agreement.

 

Subject to the conditions set forth in
the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end
of such Exercise Period, such Warrants shall become void.

 

Reference is hereby made to the further
provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have
the same effect as though fully set forth at this place.

 

This Warrant Certificate shall not be
valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

 

    	 

    	 

    

  

This Warrant Certificate shall be governed
by and construed in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles
thereof.

 

 IN WITNESS WHEREOF, the parties hereto
have caused this Warrant Certificate to be duly executed as of the date first above written.

 

	 	NeuroMetrix, Inc.
	 	 
	 	By:	 
	 	 	Name:	Thomas Higgins
	 	 	Title:	Chief Financial Officer
	 	 	 
	 	American Stock Transfer & Trust Company, LLC, as Warrant Agent
	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

    	 

    	 

    

 

[Form of Warrant Certificate]

 

[Reverse] 

 

The Warrants evidenced by this Warrant
Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive shares of Common Stock
and are issued or to be issued pursuant to a Warrant Agreement dated as of April [•], 2015 (the “Warrant Agreement”),
duly executed and delivered by the Company to American Stock Transfer & Trust Company, LLC, as warrant agent (the “Warrant
Agent”), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and
is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the
Warrant Agent, the Company and the holders (the words “holders” or “holder” meaning the Registered
Holders or Registered Holder) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written
request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to
them in the Warrant Agreement.

 

Warrants may be exercised at any time
during the Exercise Period set forth in Section 3.3 of the Warrant Agreement. The holder of Warrants evidenced by this Warrant
Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon
properly completed and executed, together with payment of the Exercise Price as specified in the Warrant Agreement (or through
“cashless exercise” as provided for in the Warrant Agreement) at the office of the Warrant Agent designated
for such purpose. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less
than the total number of Warrants evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new
Warrant Certificate evidencing the number of Warrants not exercised.

 

Notwithstanding anything else in this
Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement
covering the shares of Common Stock to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder
relating to the shares of Common Stock is current, except through “cashless exercise” as provided for in the Warrant
Agreement.

 

The Warrant Agreement provides that upon
the occurrence of certain events the number of shares of Common Stock issuable upon exercise of the Warrants set forth on the face
hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to
receive a fractional interest in a share of Common Stock, the Company shall, upon exercise, round up to the nearest whole number
of shares of Common Stock to be issued to the holder of the Warrant.

 

Warrant Certificates, when surrendered
at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal representative
or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant
Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing
in the aggregate a like number of Warrants.

 

Upon due presentation for registration
of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant Certificates of
like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this
Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax or other governmental
charge imposed in connection therewith.

 

    	 

    	 

    

 

The Company and the Warrant Agent may
deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation
of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s)
hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.
Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of the Company.

 

    	 

    	 

    

 

Election to Purchase

 

(To Be Executed Upon Exercise of Warrant)

 

The undersigned hereby irrevocably elects
to exercise the right, represented by this Warrant Certificate, to receive shares of Common Stock and herewith tenders payment
for such shares to the order of NeuroMetrix, Inc. (the “Company”) in the amount of $________ in accordance with
the terms hereof. The undersigned requests that a certificate for such shares be registered in the name of ________, whose address
is and that such shares be delivered to whose address is ________. If said number of shares is less than all of the shares of Common
Stock purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of such
shares be registered in the name of , whose address is , and that such Warrant Certificate be delivered to , whose address is .

 

In the event that the Warrant is to be
exercised on a “cashless” basis pursuant to Section 3.3.2 of the Warrant Agreement, the number of shares that
this Warrant is exercisable for shall be determined in accordance with Section 3.3.2 of the Warrant Agreement.

 

	 	 	
 

	 	a “Cash Exercise” with respect to Warrant Shares; and/or
	 	 	 
	 	 	
 

	 	a “Cashless Exercise” with respect to Warrant Shares, resulting in a delivery obligation by the Company to the Holder of shares of Common Stock representing the applicable Net Number, subject to adjustment.

 

In the event that the Warrant may be exercised,
to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of shares that this Warrant is exercisable
for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless exercise
and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented
by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive shares of Common Stock.
If said number of shares is less than all of the shares of Common Stock purchasable hereunder (after giving effect to the cashless
exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such shares be registered
in the name of ________, whose address is ________, and that such Warrant Certificate be delivered to , whose address is .

 

	Date: ____________________, 20___ 	 	 	 	(Signature)
	 	 	 
	 	 	 	 	(Address)
	 	 	 	 	
 
	 	 	 	 	
        (Tax Identification Number)

         

        Signature Guaranteed:

         

        THE SIGNATURE(S) SHOULD BE GUARANTEED BY
        AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED
        SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).Exhibit 10.29

 

COMPANY CONSULTING AGREEMENT

 

CONSULTING AGREEMENT
effective as of February 28, 2013 between NEUROTROPE BIOSCIENCE, INC., a Delaware corporation, having a mailing address at 10732
Hawk’s Vista Street, Plantation, Florida 33324 (the “Company”) and RAMAT CONSULTING CORP., a company organized
under the laws of the State of New York, USA, having an address at 111 Jim Stephenson Road, Swan Lake, New York 12783(“ Consultant”).

 

WITNESSETH:

 

WHEREAS, the Company
is engaged in the research, design and development, of proprietary technologies and pharmaceuticals for the diagnosis and treatment
of Alzheimer’s Disease and licenses, owns and controls intellectual property relating thereto;

 

WHEREAS, simultaneous
with the execution of this agreement, NTR21 Holdings, LLC, a New York limited liability company controlled by Charles S. Ramat
(“NTR”), is purchasing $1,000,000 of Series A Preferred shares of the Company, and the Company and NTR have entered
into a Series A Preferred Stock Purchase Agreement (the “Share Purchase Agreement”) relating to such shares (the “NTR
Shares”);

 

WHEREAS, Consultant
is owned and controlled by Charles S. Ramat.

 

WHEREAS, in view of
Mr. Ramat’s and Consultant’s expertise in the strategic development of business enterprises, the Company desires to
retain Consultant to provide business development and marketing consulting services to the Company, all upon the terms and subject
to the conditions hereinafter set forth;

 

NOW, THEREFORE,
in consideration of the mutual premises, covenants and agreements set forth below and intending to be legally bound, the parties
hereto agree as follows:

 

1.           Retention
of Consultant; Term. (a) The Company hereby agrees to retain the Consultant, and the Consultant hereby agrees to serve,
as an independent consultant to the Company, in accordance with the terms and provisions of this Agreement, during the Consulting
Term. The Consulting Term shall initially be set at five years from the date of this Agreement, and thereafter, will be automatically
renewed from year to year on March 1st of each year, without any further action by the parties, unless either the Company or Consultant
notifies the other party in writing at least sixty (60) days prior to the expiration of the Consulting Term then in effect that
it does not desire to renew this Agreement

 

(b)           The
Company may terminate the Consulting Term for “Cause”, upon thirty (30) days written notice describing the circumstances
thereof in reasonable detail (during which time Consultant shall have the opportunity to explain the situation and correct any
misunderstandings). As used herein, the term “Cause” shall mean: (i) any material breach of this Agreement by the Consultant;
(ii) any willful or gross neglect by the Consultant of his duties and responsibilities hereunder; (iii) any fraud, criminal misconduct,
breach of fiduciary duty, dishonesty, gross negligence or willful misconduct by the Consultant in connection with the performance
of his duties and responsibilities hereunder; (iv) the intoxication of Consultant or Consultant being under the influence of illegal
or illegally obtained drugs during business hours or while on call, or Consultant’s habitual drunkenness or addiction to
drugs (provided that this shall not restrict the Consultant from taking physician-prescribed medication in accordance with the
applicable prescription); (v) the commission by the Consultant of any (A) felony or (B) crime or act of moral turpitude; (vi) any
action by the Consultant that may materially impair or damage the reputation of the Company; (vii) insubordinate disregard of any
lawful direction given to the Consultant by the Board; or (viii) failure or refusal to comply with the Company’s lawful policies
and procedures.

 

    	 

    	 

    

 

(c)           Consultant
may terminate the Consulting Term for “Good Reason”. For purposes of this Agreement, “Good Reason” shall
mean that the Company has failed to pay Consultant any compensation or reimbursements due to Consultant under Sections 3 or 4 of
this Agreement, or the Company has breached any of its representations, warranties or covenants under this Agreement, or the Company
or its management has engaged in willful and intentional acts of fraud or illegal activity involving the Company, and any such
failure, breach or default continues uncured after ten (10) days written notice from Consultant to the Company describing the circumstances
thereof in reasonable detail (during which time the Company shall have the opportunity to explain the situation and correct any
misunderstandings).

 

2.           Consulting
Services of Consultant.

 

(a)           The
consulting services to be performed by Consultant as an independent consultant to the Company during the Consulting Term shall
include providing business development and marketing consulting services as reasonably requested by the Company.

 

(b)           Consultant
shall make available Mr. Charles S. Ramat to provide consulting services for the Company, on a part-time basis, although there
is no minimum time commitment. Consultant may provide services either from Consultant’s or Mr. Ramat’s own home or
offices, or via telephone or video conference calls, emails, text, or other methods of communication. Recognizing that the Company’s
facilities are virtual and the Company may have or utilize facilities in West Virginia, Maryland, Florida and other locations and
Consultant is normally based in New York, Consultant will render services from New York except upon Company approved and reimbursed
travel to the Company’s facilities. Consulting services which shall count towards Consultant’s obligations shall include
time spent at meetings, presentations and calls and on research and analysis relating to the Company, regardless of location, as
well as travel time, whether out of town or locally. Consultant may schedule services to the Company, at their mutual convenience,
and the Company recognizes that there may be weeks when Mr. Ramat is traveling on vacation or other business and work for the Company
will be rescheduled for other times.

 

(c)           In
order to make the most effective use of Consultant’s services, the Company will cause the Company’s directors, executive
officers, key personnel and professional advisors to speak and meet with Mr. Ramat on a regular basis, and to enable Mr. Ramat
to attend, at his option and as an Observer, the Company’s Board of Directors meetings (as more fully described in Section
7 of this Agreement), management committee meetings and meetings with professional advisors (which may be accomplished by video
or audio conference calls). The Consultant and Company shall cooperate to mutually schedule such meetings to facilitate Mr. Ramat’s
participation.

 

    	-2-

    	 

    

 

(d)           To
further the effectiveness of Consultant’s services, the Company shall keep the Consultant informed of all material transactions
and events concerning the Company, and the Company will provide to Consultant, all material information regarding the Company,
including financial, management and operations reports, business plans, investment offering materials, term sheets, letters of
intent, leases, licenses and contracts for proposed and completed transactions, patent and other technology descriptions, brochures
and reports, and other marketing information.

 

(e)           Consultant
and Mr. Ramat shall maintain any such information provided to them regarding the Company which is non-public and proprietary in
confidence and shall not use, disclose or transfer such information for purposes competitive or adverse to the Company. However,
the Company acknowledges that Consultant’s services with respect to the Company include attending and participating in meetings,
calls and communications and providing information regarding the Company in presentations and negotiations, with professional advisors,
investors, lenders, underwriters, customers, joint venturers, licensees, consultants, contractors and other counterparties of the
Company, and any of such Consultant’s and Mr. Ramat’s activities on behalf of the Company shall be permissible. Further,
Consultant and Mr. Ramat shall be entitled to disclose such Company information in response to court orders, subpoenas and other
legal process, after notifying the Company of such requests so the Company has the opportunity to challenge or limit such request.

 

(f)           The
Consultant shall operate under the reasonable direction of the Board of Directors of the Company. The Consultant shall not have
authority to undertake Company obligations or liabilities and all contracts, applications, proposals or other legal commitments
shall be signed by an appropriate officer of the Company and shall be solely the obligation of the Company.

 

3.           Consulting
Fees.           (b) As compensation for the services to be
rendered by Consultant pursuant to this Agreement during the Consulting Term, the Company agrees to pay to
Consultant a monthly fee of Four Thousand One Hundred and Sixty Seven Dollars ($4,167) Dollars ($50,000 annually), to be wire
transferred to Consultant’s account on or before the first day of each calendar month (with the first such payment to
be made on or before the execution of this Agreement).

 

(b)           Since
the Consultant is an independent contractor of the Company and not an employee, there will be no withholding for taxes from any
payments due to Consultant under this Agreement.

 

4.           Reimbursement
of Expenses. (c) Consultant shall be reimbursed for all pre-approved travel in connection with the Consultant’s services
to the Company, including without limitation, any travel to the Company’s facilities in Maryland, West Virginia, or Florida.
Any Consultant air travel will be “Business Class”.

 

(b)           Consultant
shall also be reimbursed, upon submission to the Company of appropriate vouchers and receipts, for all other out-of-pocket expenses
reasonably incurred by Consultant in furtherance of the Company’s business.           

 

    	-3-

    	 

    

 

(c)           Such
reimbursements shall be paid promptly after the required submissions, and in no event less frequently than monthly.

 

5.           Survival
of Payment Obligations After any Termination.

 

In the event of any
termination or expiration of the Consulting Term or this Agreement, the Company shall remain obligated and shall pay to Consultant,
within ten (10) business days of the termination or expiration date, (i) all unpaid monthly compensation through the termination
date and (ii) all unreimbursed expenses payable to Consultant pursuant to Section 4 above.

 

6.           No
Joint Venture, Etc.

 

(a)           The
Consultant and the Company shall be independent contractors and nothing in this Agreement shall be construed as creating a partnership,
joint venture, employment or agency relationship between the Company or Consultant.

 

(b)           Consultant
does not represent, warrant, guarantee or ensure any particular business results from the services which may be performed for the
Company pursuant to this Agreement.

 

(c)           In
the event that Consultant refers or introduces to the Company, or arranges for the Company to utilize the services of, third parties
such as attorneys, accountants, investment bankers, brokers, finders, sales or marketing representatives, contractors or other
consultants, such third parties will be direct contractors for the Company and not Consultant and their fees, commissions, disbursements
and other charges will be the sole responsibility of the Company. Consultant is not providing any licensed professional services
under this Agreement and the Company shall retain and rely upon its own attorneys, accountants, tax advisors, securities broker
dealers, underwriters, engineers, appraisers and other licensed professionals.

 

(d)           The
Company acknowledges that, in connection with Consultant’s performance of its services hereunder, Consultant and Mr. Ramat
at all times are entitled to rely, as to accuracy and completeness, upon information furnished to them by the Company’s directors,
officers, employees, professional advisors and agents.

 

(e)           Neither
Consultant nor any of his affiliates assumes, assures, endorses or guarantees or shall have any responsibility for any liability,
obligation or contract of the Company.

 

(f)           The
Company shall provide advance written notice to the Consultant prior to including the name or identification of Consultant or Mr.
Ramat or their affiliates in any application, filing, report or registration with any governmental or regulatory agency or any
prospectus, offering memo, brochure, proposal or other marketing materials, and unless there is a legal requirement compelling
such disclosure, the Consultant’s and Mr. Ramat’s written consent shall be required for such use or disclosure.

 

    	-4-

    	 

    

 

(g)           The
Company does hereby indemnify Consultant, Mr. Ramat and their heirs, personal representatives, successors and assigns (“Consultant
Indemnified Parties”) and agree to defend and hold them harmless from and against any and all claims, damages, charges, liabilities,
losses, judgments, fines, penalties, amounts paid in settlement or satisfaction of claims, costs and expenses (including without
limitation reasonable attorneys’ fees and expenses) arising out of, relating to or accruing in respect of (i) liabilities
and obligations of the Company or its business, products or assets, and claims relating to the conduct of the Company’s business,
including, without limitation, liabilities for taxes, regulatory fines, assessments and penalties, and any claims or disputes of
the Company with customers, doctors, patients, hospitals or other medical providers, insurers, investors, lenders, licensees, licensors,
consultants, contractors, employees or others and (ii) any breach or violation of any representation, warranty, covenant or obligation
of the Company under this Agreement. The rights of indemnification provided by this Section 6(g) shall be in addition to, and not
be deemed exclusive of, any other rights and remedies apart from this Agreement which may be available to Consultant or Mr. Ramat,
whether pursuant to the Share Purchase Agreement or by any other contract, at law, in equity or otherwise.

 

7.           Observer
to the Board of Directors.           (d)   Effective immediately, Mr. Ramat shall be appointed as an Observer to the Board of Directors
of the Company, and such appointment shall be ratified by the Board of Directors at its very next meeting and/or written consent
on or after the date of this Agreement. Mr. Ramat shall continue to be an Observer to the Board of Directors of the Company throughout
the Consulting Term, and if necessary, the Board of Directors shall re-appoint and re-confirm such appointment an Observer from
time to time.

 

(b)           As
an Observer to the Board of Directors, Mr. Ramat shall have all of the same rights as a member of the Board of Directors, under
the Company’s Certificate of Incorporation, By-Laws, and applicable law, other than the right to vote. Such rights afforded
to Mr. Ramat shall include, without limitation, notice of, and the right to attend and participate in and speak at, all Board of
Directors meetings, whether held in person or by conference telephone or video or on-line, and the right to review in advance all
proposed written consents and actions of the Board of Directors; the right to receive all minutes and reports of Board of Directors
meetings and actions by written consent; and the right to receive all financial and other reports, presentations and information
referred to in Section 2(d) which may be provided to Directors; and the right to be informed of all material transactions and events
concerning the Company; and the right to meet and speak with the Company’s directors, executive officers, key personnel and
professional advisors as referred to in Section 2(c).

 

(c)           The
Company will indemnify Mr. Ramat to the fullest and same extent as the Company provides indemnification to its Directors from time
to time under the Company’s Certificate of Incorporation, By-Laws and applicable law, and under the Company’s policies
of Directors and Officers Liability Insurance. The Company will take steps to assure that Mr. Ramat, even though an Observer, is
covered by the Company’s policies of Directors and Officers Liability Insurance.

 

(d)           The
Company will provide compensation to Mr. Ramat in the same amounts as the Company provides to its Directors for service in the
capacity of a Director.

 

(e)           The
Company will reimburse Mr. Ramat for all reasonable out of pocket expenses, including travel expenses, to attend and participate
in Board of Directors meetings.

 

    	-5-

    	 

    

 

8.           Stock
Options Granted to Mr. Ramat.

 

(a)           The
Company does hereby grant to Mr. Ramat options to purchase Three Hundred Thousand (300,000) shares of the Company’s Common
Stock, at an exercise price of One ($1.00) per share (the “Options”). The Options may be exercised for a term of ten
(10) years from the date each Option becomes fully vested. To the fullest extent possible the terms and conditions of the Options
granted to Mr. Ramat will follow the Common Stock Purchase Agreement provided to Jim New, the CEO of the Company, except that Mr.
Ramat shall receive options for Common Stock rather than issued shares of Common Stock.

 

(b)           As
with Mr. New’s agreement, Twenty (20%) percent of Mr. Ramat’s Options shall vest immediately upon the date of this
Agreement, and the balance of Eighty (80%) shall vest fractionally on a day by day basis over the subsequent 4 year term from the
date of this Agreement ( 240,000 shares / 1460 days = 164 shares vest each day of the consulting agreement). An acceleration of
this vesting schedule may be awarded at the discretion of Neurotrope’s Board of Directors in the event the Consultant is
instrumental in assisting the Company in further capital raising activities. Also similar to Mr. New’s agreement, all of
the Options granted to Mr. Ramat will vest upon the earlier to occur of (i) a “Deemed Liquidation Event” or a “Fundamental
Change” or a “Change of Ownership” of the Company as such terms may be defined in the Certificate of Incorporation
of the Company and (ii) upon the effective date of a registered public offering of the Company’s Common Stock.

 

(c)           In
the event that the Company has validly terminated the Consulting Term for “Cause” pursuant to Section 1(b) of this
Agreement, then any Options which were scheduled to vest after the effective date of termination shall not vest, but Mr. Ramat
shall retain all rights as to Options which were scheduled to vest prior to the effective date of termination.

 

(d)           The
Options granted to Mr. Ramat shall not be transferable except (i) by will or intestate devise or (ii) to family members, family
trusts or controlled companies for estate planning purposes. Any such transferee of the Options shall take subject to the terms
and conditions of this Agreement.

 

(e)           Any
vested Option may be exercised in whole or in part by the holder sending written notice to the Company of the number of Options
to be exercised and the total exercise price to be paid, and upon submission of a check or wire transfer for the total exercise
price, the Company shall issue and deliver to the holder a stock certificate for the shares for which the Option is exercised.
The shares shall bear an appropriate legend indicating they are restricted securities subject to applicable securities laws. The
Company shall at all times from and after the date of this Agreement until the last Option term for exercise has expired, reserve
the number of shares of Common Stock necessary to satisfy all Options that may be exercised.

 

(f)           Mr.
Ramat, shall, with respect to the shares to be issued upon exercise of the Options, have and be entitled to all rights that the
other holders of Common Stock of the Company have pursuant to the Stockholders Agreement dated October 31,2012, including without
limitation, First Refusal Rights; Tag Along Rights; Drag Along Rights and Obligations;

 

    	-6-

    	 

    

 

(g)           In
addition, Mr. Ramat shall, with respect to the shares to be issued upon exercise of the Options, have and be entitled to all rights
set forth in the Investors’ Rights Agreement dated on or about February 28, 2013, including Registration Rights and Rights
to Future Stock Issuances.

 

9.           Notices.
Any notices and other communications hereunder shall be in writing and shall be deemed to have been duly given when mailed by first
class registered or certified, postage prepaid, to their addresses as set forth above, or by courier delivery or by fax or email
with confirmed receipt, or to such other address as shall be designated by such party by notice given in accordance herewith.

 

Copies of all notices
to the Company shall be sent to

 

James New                                            

CEO                                                         

Neurotrope
Bioscience                            

                                                                  

Tel: 954 632
6630                                   

Fax: 954 452
4656                                  

Email: jnew@neurotropebioscience.com

 

Copies of all notices
to the Consultant shall be sent to

 

Lawrence M. Levinson,
Esq.

Troutman Sanders LLP

The Chrysler Building

405 Lexington Avenue

New York, New York 10174

Tel: 212 - 704 - 6251

Fax: 212 - 704 - 5955

Email: Lawrence.levinson@troutmansanders.corn

 

10.           General
Provisions.

 

(a)           Any
provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition
or unenforceability in any jurisdiction shall not be invalidate or render unenforceability such provision in any other jurisdiction.

 

(b)           No
failure to exercise nor any delay in exercising on the part of any party of any right, power or privilege hereunder shall operate
as a waiver thereof; not shall any single or partial exercise of any right, power or privilege hereunder preclude any other or
further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided are cumulative
and may be exercised singly or concurrently, and are not exclusive of any rights or remedies provided by law.

 

    	-7-

    	 

    

 

(c)           None
of the terms or provisions of this Agreement may be waived, altered, modified or amended except by an instrument in writing, duly
executed by Consultant and the Company. This Agreement shall inure to the benefit of and be enforceable by and binding upon Consultant
and the Company and their respective heirs, personal representatives, successors and assigns. Neither the Company nor Consultant
shall transfer or assign their rights or obligations under this Agreement.

 

(d)           Each
of the parties hereto shall cooperate and take such actions, and execute such other documents and instruments, as may be reasonably
requested by the others in order to carry out the provisions and purposes of this Agreement.

 

(e)           This
Agreement may be executed in counterpart copies and each of which shall be an original but all of which shall constitute a single
instrument.

 

(f)           The
provisions and covenants set forth in this Agreement are for the benefit of the parties to this Agreement and not for the benefit
of any third party or other person, and no third party or other person shall have any right to enforce the provisions and covenants
against any party hereto.

 

(g)           This
Agreement shall be construed and governed by the laws of the State of New York. Each party hereto for himself, itself and his or
its heirs, personal representatives, successors and assigns, hereby consents to personal jurisdiction over him, it and them in
the federal and state courts located in the State of New York. The Consultant may enforce this Agreement both in New York and any
state where the Company is located.

 

(h)           The
Company represents and warrants to Consultant that this Agreement has been duly authorized by all necessary corporate action, has
been duly executed and delivered and constitutes the legal, valid and binding obligation of the Company enforceable in accordance
with its terms.

 

(i)           The
Company will require any successor (whether direct or indirect, by purchase of assets or capital stock, merger, consolidation or
otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree in writing to
perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession
had taken place. As used in this Agreement, the “Company” shall mean the Company as hereinabove defined and any successor
to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.           

 

    	-8-

    	 

    

 

IN WITNESS WHEREOF,
the Company and Consultant have caused this Agreement to be executed as of the day and year first above written.           

 

	 	NEUROTROPE BIOSCIENCE, INC.

 

	 	By:	/s/ James New

 

	 	Printed Name:	James New

 

	 	Title:	CEO Neurotrope Bioscience

 

 

	 	RAMAT CONSULTING CORP.
	 	 	 
	 	By:	/s/ Charles Ramat
	 		Charles S. Ramat, President

 

 

 

    	-9-

    	 

    

 

AMENDMENT TO CONSULTING AGREEMENT

 

           AMENDMENT dated
December 18, 2013 to CONSULTING AGREEMENT effective as of February 28, 2013 between NEUROTROPE BIOSCIENCE, INC., a Delaware corporation,
having a mailing address at 10732 Hawk’s Vista Street, Plantation, Florida 33324 (the “Company”) and RAMAT CONSULTING
CORP., a company organized under the laws of the State of New York, USA, having an address at 111 Jim Stephenson Road, Swan Lake,
New York 12783 (“Consultant”).

 

WITNESSETH:

 

WHEREAS, the Company
is engaged in the research, design and development, of proprietary technologies and pharmaceuticals for the diagnosis and treatment
of Alzheimer’s Disease and licenses, owns and controls intellectual property relating thereto;

 

WHEREAS, Consultant’s
services are performed by Mr. Charles Ramat who owns and controls Consultant and the Company would like to assign to Consultant
additional responsibilities to assist the Board of Directors of the Company in developing, synthesizing and refining a strategic
plan for development of the Company’s technology, and to set forth the parameters for such assignment, and Consultant
is willing to undertake such assignment on the terms set forth in this Amendment;

 

NOW, THEREFORE,
in consideration of the mutual premises, covenants and agreements set forth below and intending to be legally bound, the parties
hereto agree as follows:

 

1.           Scope
of Assignment.

 

(a)           The
Company hereby authorizes and directs Consultant to assist the Board of Directors in developing, synthesizing and refining a strategic
plan for development of the Company’s technology, and to meet with and obtain input from, the Company’s directors,
officers, key employees, technical personnel, consultants and advisors. Consultant may attempt to synthesize and reconcile alternative
viewpoints, to facilitate discussions among such Company personnel and consultants, and/or recommend approaches and alternatives.
Consultant can arrange such communications as and when convenient for his schedule. Consultant does not provide any assurances,
and the Company and the Board recognize there are no assurances, that any particular plan or result can be developed or achieved
through the efforts of Consultant.

 

(b)           Consultant
and Mr. Ramat shall report solely to the Board of Directors of the Company, which is anticipated to be verbal updates from time
to time. Consultant shall merely be providing information, recommendations or viewpoints to the Board, and the Board of Directors
of the Company shall have the responsibility of acting upon and making decisions with respect to any input provided by Consultant,
and any actions or decisions so taken by the Board of Directors shall be solely the obligations of the Company. .

 

(c)           The
Company and the Board shall rely upon their counsel, tax advisors and accountants with respect to any legal, securities, tax or
accounting aspects of any technical development plan, information, discussions, recommendations or viewpoints relating thereto,
whether presented by Consultant or other Company personnel or advisors, and neither Consultant nor Mr. Ramat are providing any
legal, securities, tax or accounting advice.

 

(d)           The
Company’s Board of Directors, in consultant with counsel, shall have the responsibility of determining whether any
disclosures, reports or filings are necessary, either within the Company or in public filings or releases , with respect to
any technical development plan, information, discussions, recommendations or viewpoints relating thereto, whether presented
by Consultant or other Company personnel or advisors, and if any are determined to be necessary, the Board and counsel shall
prepare the contents thereof.           

 

    	 

    	 

    

 

(e)           In
providing such assistance to the Board of Directors, the Consultant may obtain confidential information regarding the Company
and it technology, which shall be maintained as such, but the Company and the Board acknowledge that inherent to the
Consultant’s assignment is discussion of such information with Company personnel and consultants, and Consultant is
permitted to discuss and utilize such confidential information for purposes of carrying out the assignment under this
Amendment.

 

(f)           Consultant
shall be reimbursed for any out of town travel or other out of pocket expenses incurred by Consultant or Mr. Ramat in connection
with the foregoing assignment, in the manner provided in the Consulting Agreement.

 

2.           Indemnification.

 

(a)           The
Company does hereby indemnify Consultant, Mr. Ramat and their heirs, personal representatives, successors and assigns (“Consultant
Indemnified Parties”) and agree to defend and hold them harmless from and against any and all claims, damages, charges, liabilities,
losses, judgments, fines, penalties, amounts paid in settlement or satisfaction of claims, costs and expenses (including without
limitation reasonable attorneys’ fees and expenses) arising out of relating to or accruing in respect of any claims, liabilities
and obligations (of the Company, the Board of Directors of the Company, or otherwise) relating to or arising out of Consultant’s
or Mr. Ramat’s activities on behalf of the Company relating to the assistance and assignment described in this Agreement,
or any technical development plan or recommendations or actions omissions of the Company or the Board of Directors or any Company
personnel relating hereto, including without limitation, any claims under federal, state or foreign securities laws. The rights
of indemnification provided by this Section 2 shall be in addition to, and not be deemed exclusive of, any other rights and remedies
of Consultant or Mr. Ramat apart from this Amendment.

 

3.           General
Provisions.           

 

(a)           In
all other respects, the Consulting Agreement remains unchanged and in full force and effect, and all of the provisions of the Consulting
Agreement (not otherwise addressed herein) shall govern the relationship between Consultant and the Company.

 

(b)           This
Amendment may be executed in counterpart copies and each of which shall be an original but all of which shall constitute a single
instrument.

 

(c)           The
provisions and covenants set forth in this Amendment are for the benefit of the parties to this Amendment and Mr. Ramat and not
for the benefit of any third party or other person, and no third party or other person shall have any right to enforce the provisions
and covenants against any party hereto.

 

    	-2-

    	 

    

 

IN WITNESS WHEREOF,
the Company and Consultant have caused this Amendment to be executed as of the day and year first above written.

 

	 	NEUROTROPE BIOSCIENCE, INC.

 

	 	By:	/s/ James New

 

	 	Printed Name:	James New

 

	 	Title:	CEO

 

 

	 	RAMAT CONSULTING CORP.
	 	 	 
	 	By:	/s/ Charles Ramat
	 		Charles S. Ramat, President

 

 

    	-3-

    	 

    

 

AMENDMENT NO. 2 TO

CONSULTING AGREEMENT

 

THIS AMENDMENT NO.
2 to CONSULTING AGREEMENT dated February 2nd, 2015 (the “Amendment”) to CONSULTING AGREEMENT effective as of February
28, 2013, and as amended on December 18, 2013 (the Consulting Agreement”) between NEUROTROPE BIOSCIENCE, INC., a Delaware
corporation having an address at 50 Park Place, Suite 1401, Newark, New Jersey 07102 (the “Company”) and RAMAT CONSULTING
CORP., a company organized under the laws of the State of New York, USA, having an address at 111 Jim Stephenson Road, Swan Lake,
New York 12783 (“Consultant”).

 

WITNESSETH:

 

WHEREAS, the Company
is engaged in the research, design and development, of proprietary technologies and pharmaceuticals for the diagnosis and treatment
of Alzheimer’ s Disease and licenses, owns and controls intellectual property relating thereto;

 

WHEREAS, Consultant’s
services are performed by Mr. Charles Ramat who owns and controls Consultant and the Company and Consultant would like to amend
the Consulting Agreement to clarify Consultant’s services for the Company;

 

NOW, THEREFORE,
in consideration of the mutual premises, covenants and agreements set forth below and intending to be legally bound, the parties
hereto agree as follows:

 

1.                 
Scope of Assignment.

 

(a)               
The Company hereby authorizes and directs Consultant to provide services as follows: Mr. Ramat shall be engaged as
the Company’s President and Chief Executive Officer and shall perform all duties consistent with that position.

 

2.                 
General Provisions.

 

(a)               
In all other respects, the Consulting Agreement remains unchanged and in full force and effect, and all of the provisions
of the Consulting Agreement (not otherwise addressed herein) shall govern the relationship between Consultant and the Company;
and any ambiguities between this Amendment and the Consulting Agreement shall be governed by the Consulting Agreement

 

(b)              
This Amendment may be executed in counterpart copies and each of which shall be an original but all of which shall
constitute a single instrument.

 

(c)               
The provisions and covenants set forth in this Amendment are for the benefit of the parties to this Amendment and
Mr. Ramat and not for the benefit of any third party or other person, and no third party or other person shall have any right to
enforce the provisions and covenants against any party hereto.

 

    	 

    	 

    

 

 

IN WITNESS WHEREOF,
the Company and Consultant have caused this Amendment to be executed as of the day and year first above written.

 

	 	NEUROTROPE BIOSCIENCE, INC.

 

	 	By:	/s/ Robert Weinstein

 

	 	Printed Name:	Robert Weinstein

 

	 	Title:	Secretary

 

 

	 	RAMAT CONSULTING CORP.
	 	 	 
	 	By:	/s/ Charles Ramat
	 		Charles S. Ramat, President

 

 

 

    	-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]